Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet® at Academy 2023 New Orleans Annual Meeting

New York, Oct. 09, 2023 (GLOBE NEWSWIRE) —

In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions. This groundbreaking research will be presented at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual Meeting. Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, is leading the way in preservative-free eye care solutions.

The Optejet® is a state-of-the-art device that delivers preservative-free medications in a precise and controlled manner. This innovative technology has been proven to maintain its microbial integrity even in the most challenging environments. Eyenovia’s commitment to safety and efficacy is evident in the rigorous testing and research conducted on the Optejet.

How This Will Affect Me

As a consumer, this development has profound implications for your eye health. The preservative-free nature of the Optejet ensures that you are receiving your medication without the risk of contamination. This can lead to better outcomes and increased comfort for those in need of eye care treatments.

How This Will Affect the World

The implications of Eyenovia’s research go far beyond individual consumers. By setting a new standard for preservative-free eye care technology, Eyenovia is paving the way for safer and more effective treatments on a global scale. This breakthrough has the potential to revolutionize the way eye care is delivered around the world, ultimately improving the health and well-being of countless individuals.

Conclusion

Eyenovia’s presentation at the Academy 2023 New Orleans Annual Meeting marks a significant milestone in the field of ophthalmic technology. The data on the preservative-free microbial integrity of the Optejet® highlights the company’s commitment to innovation and safety. As we look towards the future, it is clear that Eyenovia’s groundbreaking research will have a lasting impact on both individual consumers and the global eye care community.